ACAD - NASDAQ
ACADIA Pharmaceuticals Inc.
$21.72
+3.0%ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
At a Glance
Live Snapshotacad
Operating Expenses
Last Annual Value
877.70M
3-Year CAGR
6%
5-Year CAGR
4%
10-Year CAGR
18%
ACADIA Pharmaceuticals Inc. Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 877.70M | 5.2% | 6.7% | 11.9% | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 326.06M | 97.9% | 14.3% | N/A | |
 Ligand Pharmaceuticals Incorporated NASDAQ:LGND | 214.30M | 36.5% | 23.2% | 13.9% | |
 Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 443.21M | 21.3% | 18.4% | N/A | |
 Immunovant, Inc. NASDAQ:IMVT | 532.90M | 36.8% | 37.6% | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 172.75M | 61.0% | 40.5% | 29.0% | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 466.13M | 24.8% | 25.4% | 11.2% | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 519.50M | 31.9% | 36.7% | 56.1% | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 393.34M | 57.4% | 47.8% | 39.7% | |
 Belite Bio, Inc NASDAQ:BLTE | 84.21M | 38.5% | 53.8% | N/A | |
 ADMA Biologics, Inc. NASDAQ:ADMA | 101.32M | 14.6% | 11.2% | 16.7% |
ACADIA Pharmaceuticals Inc. Fair Value Envelope
Related Guides
Continue your ACAD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.